Keith W Pratz

2 months ago | onlinelibrary.wiley.com | Keith W Pratz |Harry Erba

1 Introduction Acute myeloid leukemia frontline therapy has evolved very little from the development of infusion cytarabine and daunorubicin (7 and 3) combinations described initially by Crowther in 1970 [1] and Yates in 1973 [2]. Of note, these studies reported complete remission rates of 60% and 65% respectively which is similar to CR rates currently seen with 7 and 3 in unselected AML patients.

Feb 12, 2024 | onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more

1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.